Transferrin Receptor Hijacking Delivers a 1,000-Fold Brain Exposure Leap for Oligonucleotides

The 2026 Alzheimer disease drug development landscape highlights a growing shift toward diverse disease-modifying strategies, from amyloid and tau targeting to metabolic and neuroprotective approaches.

The extended-release oral combination of dextromethorphan-bupropion uses a different mechanism of action than antipsychotic medications, which clinicians sometimes prescribe for patients with Alzheimer's disease who also experience agitation. But whether the new medication will be used as a first-line treatment is up for debate.

More than seven years of development, over $60 million in funding and a series of early clinical studies have led to this: Allyx Therapeutics is preparing for what may be the most consequential test in the New Haven-based biotech startup’s history.

Anti-amyloid drugs have transformed the Alzheimer’s disease (AD) treatment landscape, marking the first time clinicians have had access to disease-modifying treatments. Yet their use is limited to a relatively small subset of patients with early symptomatic disease.

Out now is the 10th annual Alzheimer's Drug Development Pipeline Report.

Several local and regional startups were showcased recently at UNLV Innovation Day, where Dr. Jeffrey Cummings, director of the Chambers-Grundy Center for Transformative Neuroscience in the Department of Brain Health at the Kirk Kerkorian School of Medicine at UNLV, was excited about the growth of the life sciences ecosystem.

While Alzheimer’s remains a complex disease, recent clinical trials and research efforts have expanded, emphasizing biomarkers and better patient targeting to improve drug development success rates.